Clinical Trials in Georgia

Showing 17621-17640 of 19,050 trials

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

NCT00653328

RATIONALE: There is emerging data to suggest that the optimal use of angiogenesis inhibitors may be in combination with chemotherapy. The optimal use of atrasentan may be in combination with chemotherapy in women with relapsed and refractory ovarian cancer,fallopian tube cancer, and peritoneal serous papillary adenocarcinoma. Due to its manageable toxicity profile, ease of administration, and activity in both platinum sensitive as well as platinum-resistant patients, Doxil has become the 2nd-line treatment of choice for women with advanced stage ovarian cancer that has progressed following 1st-line platinum/taxane therapy. PURPOSE: To determine if a treatment combination of atrasentan + Doxil is an effective 2nd line treatment in patients with recurrent ovarian cancer, fallopian tube cancer, or peritoneal cancer.

Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer

Vanderbilt-Ingram Cancer Center15 participantsStarted May 2003

Macon, Georgia, United States • Louisville, Kentucky, United States • Germantown, Tennessee, United States +3 more locations

COMPLETEDPhase 229 miles

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

NCT00813527

The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate.

Hyperlipidemias

Takeda213 participantsStarted Feb 2006

Huntsville, Alabama, United States • Sierra Vista, Arizona, United States • Beverly Hills, California, United States +33 more locations

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Find Trials by Condition in Georgia

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Paracor Ventricular Support System (PVSS) for Patients With Heart Failure

Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol in Patients 12 Years and Older With SAR

Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain

Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia

Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

Dose Escalation Study With QLT0074 for Benign Prostatic Hyperplasia

A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS

Safety Profile, MTD, and PK Profile Studies of ABT-263 When Administered in Combination With Standard and Weekly Regimens of Docetaxel in Subjects With Cancer

Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)